Sponsor: University of Copenhagen, Department of Haematology, Herlev Hospital

Principal investigator: Hans Carl Hasselbalch

Primary objective: To quantify JAK2 mutation allele burden at diagnosis and after interferon therapy in a large cohort (approximately 100) patients with PV. ET and PMF. To corroborate a high correlation between JAK2 mutation allelle burden in bone marrow and peripheral blood in patients with a low allele burden.

Status: 90 patients included in Denmark.

Start: Spring 2009.

Research support: Scering-Plough Denmark

Study design: Retrospective analysis of marrow samples at diagnosis are compared to samples obtained after or during interferon therapy. All JAK2 analyses are done centrally.

Contact person: Hans Carl Hasselbalch